Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 210 resultater
Tid
Selskap
Tittel
Sektor
Kategori
27 Jun 2024
19:22 CEST
ABIONYX PHARMA
ABIONYX Pharma annonce l’approbation à l’unanimité de l’ensemble des résolutions soumises au vote lors de son Assemblée Générale Mixte
20103010 Biotechnology
General meeting / Board Meeting
27 Jun 2024
19:22 CEST
ABIONYX PHARMA
ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting
20103010 Biotechnology
General meeting / Board Meeting
19 Jun 2024
21:14 CEST
ABIONYX PHARMA
ABIONYX décide une augmentation de capital avec suppression du droit préférentiel de souscription au profit d’une catégorie de personnes par émission d’ABSA d’un montant d’environ 3,4M€
20103010 Biotechnology
Other subject
19 Jun 2024
21:14 CEST
ABIONYX PHARMA
ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million
20103010 Biotechnology
Other subject
13 Jun 2024
19:48 CEST
ABIONYX PHARMA
ABIONYX Pharma a passé avec succès la réunion pré-IND avec la FDA pour une étude clinique de phase 2b/3 évaluant CER-001 dans le traitement de patients atteints de sepsis
20103010 Biotechnology
Other subject
13 Jun 2024
19:48 CEST
ABIONYX PHARMA
ABIONYX Pharma has completed a successful pre-IND meeting with the FDAfor CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
20103010 Biotechnology
Other subject
04 Jun 2024
18:45 CEST
ABIONYX PHARMA
ABIONYX: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
04 Jun 2024
18:45 CEST
ABIONYX PHARMA
ABIONYX : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
27 May 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
27 May 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX PHARMA : DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS
20103010 Biotechnology
Other subject
27 May 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
16 May 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma fait le point sur son activité et sa position de trésorerie du 1er trimestre 2024
20103010 Biotechnology
Sales
16 May 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024
20103010 Biotechnology
Sales
07 May 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
07 May 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
02 May 2024
18:15 CEST
ABIONYX PHARMA
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023
20103010 Biotechnology
Other subject
02 May 2024
18:15 CEST
ABIONYX PHARMA
ABIONYX Pharma : Mise à disposition du document d’enregistrement universel pour l’année 2023
20103010 Biotechnology
Other subject
10 Apr 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma: Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
10 Apr 2024
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
14 Mar 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma – Bpifrance soutient le développement de CER-001 dans l’ophtalmologie par une aide à l’innovation d’environ 1 million d’euros non dilutif
20103010 Biotechnology
Other subject
14 Mar 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
20103010 Biotechnology
Other subject
11 Mar 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
11 Mar 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
11 Mar 2024
07:30 CET
ABIONYX PHARMA
ABIONYX Pharma annonce ses résultats annuels 2023
20103010 Biotechnology
Income
11 Mar 2024
07:30 CET
ABIONYX PHARMA
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results
20103010 Biotechnology
Income
07 Mar 2024
19:44 CET
ABIONYX PHARMA
ABIONYX Pharma annonce son calendrier de communication financière pour l’exercice 2024
20103010 Biotechnology
Other subject
07 Mar 2024
19:44 CET
ABIONYX PHARMA
ABIONYX Pharma announces its financial calendar for the year 2024
20103010 Biotechnology
Other subject
29 Feb 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 4th Quarter 2023
20103010 Biotechnology
Sales
29 Feb 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma fait le point sur son activité et sa position de trésorerie du 4ème trimestre 2023
20103010 Biotechnology
Sales
16 Feb 2024
08:10 CET
ABIONYX PHARMA
ABIONYX Pharma: Clarification About Clinical Results From the Phase 3 of apoA-I study, CSL112
20103010 Biotechnology
Other subject
16 Feb 2024
08:10 CET
ABIONYX PHARMA
ABIONYX Pharma : Précisions à propos des résultats cliniques de l'étude de phase 3 de l'apoA-I, CSL112
20103010 Biotechnology
Other subject
15 Feb 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112
20103010 Biotechnology
Other subject
15 Feb 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma prend acte des résultats cliniques de l'étude AEGIS-II de phase 3 évaluant l'efficacité et l'innocuité de l'apoA-I dérivée du plasma humain, CSL112 de CSL Behring
20103010 Biotechnology
Other subject
06 Feb 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Legal
06 Feb 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Legal
08 Jan 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma annonce la nomination du Dr Rob Scott au poste de Chief Medical Officer et Head of R&D
20103010 Biotechnology
Other subject
04 Jan 2024
18:53 CET
ABIONYX PHARMA
ABIONYX Pharma : Bilan semestriel du contrat de liquidité contracté avec la Société TP ICAP (Europe) SA
20103010 Biotechnology
Other subject
04 Jan 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma : Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
04 Jan 2024
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
18 Dec 2023
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma réussit la fabrication d’un troisième lot d’apoA-I humaine recombinante CER-001 selon le nouveau bioprocédé industriel innovant et robuste
20103010 Biotechnology
New
18 Dec 2023
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma Successfully Manufactures a Third Batch of Recombinant Human apoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess
20103010 Biotechnology
New
04 Dec 2023
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
04 Dec 2023
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
23 Nov 2023
19:38 CET
ABIONYX PHARMA
ABIONYX Pharma présente les résultats précliniques de CER‑001 dans le Brain Fog (brouillard cérébral), à l’occasion du 1er congrès scientifique international dédié à l’interaction Cerveau-Rein à Naples les 23 et 24 novembre 2023
20103010 Biotechnology
New
23 Nov 2023
19:38 CET
ABIONYX PHARMA
ABIONYX Pharma presents preclinical results for CER-001 in Brain Fog, at the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023
20103010 Biotechnology
New
21 Nov 2023
07:00 CET
ABIONYX PHARMA
ABIONYX Pharma announces new positive results in a uveitis model for the strategic development of the first class of biomedicines in ophthalmology based on its recombinant apoA-I
20103010 Biotechnology
Other subject
21 Nov 2023
07:00 CET
ABIONYX PHARMA
ABIONYX Pharma annonce de nouveaux résultats positifs dans un modèle d’uvéite pour le développement stratégique de la première classe de biomédicaments en ophtalmologie à partir de son apoA-I recombinante
20103010 Biotechnology
Other subject
16 Nov 2023
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma annonce son chiffre d’affaires, sa position de trésorerie et fait le point sur l’activité du 3ème trimestre 2023
20103010 Biotechnology
Sales
16 Nov 2023
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma Provides an Update on Its Activity, Its Revenue and Its Cash Position for the Third Quarter of 2023
20103010 Biotechnology
Sales
06 Nov 2023
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva